Zai Lab Ltd. has entered into a new strategic collaboration and worldwide license agreement with Medilink Therapeutics (Suzhou) Co. Ltd. to use Medilink’s TMALIN antibody-drug conjugate (ADC) platform ...

Researchers from Vera Salus Ricerca Srl and affiliated organizations have reported the discovery and preclinical characterization of novel sigma-1 receptor (S1R) antagonists as potential new analgesic ...

Affinia Therapeutics Inc. has nominated AFTX-201 as a development candidate for the treatment of BAG3 dilated cardiomyopathy. The gene therapy, using Affinia’s cardiotropic capsid, is given as a ...

Scientists from Taiwan have detailed the discovery and characterization of new MTHFD2 inhibitors.

Brainaurora Medical Technology Ltd. debuted on the Hong Kong stock exchange Jan. 8 with a HK$583.18 million (US$74.93 million) IPO, offering about 181.11 million shares at HK$3.22 per share.

The financing will enable progression of RG-0401.

Mural Oncology plc has nominated two new development candidates, one for its interleukin-18 (IL-18) program and one for its IL-12 program.

Beta-hemoglobinopathies are genetic blood disorders caused by mutations that impact the normal production or structure of hemoglobin.

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...